ACIP: LAIV Preferential Use Recommendation to Be Reviewed Further
Committee Hears Evidence Questioning Vaccine's Effectiveness in Young Children
November 10, 2014 04:09 pm Chris Crawford ? The CDC's Advisory Committee on Immunization Practices (ACIP) recommendation regarding use of live attenuated influenza vaccine (LAIV; FluMist) for children ages 2-8 just got more complicated. Recent developments, however, have not prompted any change to the ACIP's -- or the AAFP's -- recommendations for use of the vaccine.
During the ACIP's Oct. 29-30 meeting,(
www.cdc.gov) participants reviewed data from the U.S. Flu Vaccine Effectiveness Network that suggested the LAIV vaccine was not effective against the influenza A (H1N1) virus among children during the 2013-14 influenza season. That's according to AAFP liaison to the ACIP Jamie Loehr, M.D., of Ithaca, N.Y.
This unexpected finding differed from previous study results that suggested LAIV was more effective than inactivated influenza vaccine (IIV) for younger children, said a statement(
www.cdc.gov) the CDC released on Nov. 6...
